Effects of adjuvants and Toxoplasma gondii antigens on immune response and outcome of peroral T. gondii challenge

Abstract

Toxoplasma gondii antigens and adjuvants administered parenterally and perorally were tested for their ability to produce serum antibody to T. gondii, to enhance peritoneal macrophage microbicidal capacity for T. gondii, and to prevent acquisition of infection by T. gondii ingested subsequently. N-acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl (MDP) incorporated into liposomes administered intramuscularly to mice wifh 80 μg of T. gondii antigens and the synthetic adjuvant N,N-dioctadecyl-N′,N′bis (2-hydroxyethyl) propanediamine (CP 20,961) administered intramuscularly to mice with 80 μg of T. gondii lysate antigens produced the highest titres of antibody to T. gondii in sera (i.e., the mean ± S.D. of the Iog 2 of the reciprocal of the antibody titre to T. gondii measured by Sabin Feldman Dye test was 9 ± 2 in sera of mice that received T. gondii antigens plus MDP and was 8 ± 1 in sera of mice that received T. gondii antigens plus CP 20,961). No orally administered preparation produced high titres of serum antibody to T. gondii. None of the preparations which were tested protected mice against infection with T. gondii when cysts containing the parasite were administered by mouth subsequently or enhanced macrophage microbicidal capacity between two and three weeks after the last immunizations. These experiments demonstrate that presence of Toxoplasma antibody (i.e., when Iog 2 of the reciprocal of Toxoplasma antibody titres is 10 or less measured by Sabin Feldman dye test) does not protect mice against dissemination of ingested T. gondii from the gastrointestinal tract. The method of peroral challenge with T. gondii developed for this study is useful for examining effects of other potentially protective regimens in preventing acquisition of ingested T. gondii.